Merck & Co. said it achieved positive results in Phase 3 trials of its experimental insomnia treatment, a key drug in the pharmaceutical giant's pipeline.
129056
Merck achieves positive results in Phase 3 trials of insomnia drug
32698
AstraZeneca and Daiichi Sankyo to co-promote Nexium
70069
Asthma treatments work equally well
55572
XenoPort announces positive results of a Phase 1 clinical trial of XP21279
85880
Sanofi Pasteur's dengue vaccine demonstrates proof of efficacy
99475
TEVA (TEVA) provides an update on a Phase III trial for Milprosa: 1) further evidence that the
136120
Targacept launches Phase 2 study
133059
Investment pays off for Cyprotex
28502
Amgen presents data from study of the pivotal phase 3 prolia fracture trial
174711
FDA approves obesity drug Belviq
124239
Drug stocks gain;
95584
Wockhardt gains on launching generic of Wellbutrin SR in US
84817
Merck KGaA's Erbitux drug extends survival for some
1830
Pivotal study with vismodegib shows positive results in people with advanced BCC
92406
Indosolar's outlook looks positive in long run:
79889
Merck buys drug rival Schering-Plough
100334
Novartis says meningitis vaccine performed well in large trial